Humoral immune response to autologous blood transfusion in hip surgery : whole blood versus packed red cells and plasma / B. Tolksdorf, T. Frietsch, M. Quintel, M. Kirschfink, P. Becker, A. Lorentz
BACKGROUND AND OBJECTIVES: The immune response to the transfused autologous buffy coat content in whole blood has, to date, not been studied in detail. SUBJECTS AND METHODS: Patients undergoing hip arthroplasty were studied according to whether they received autologous whole blood (WB) (n = 30), autologous fresh-frozen plasma and buffy coat-poor red cells (RC) (n = 40), or no transfusion (NT) (n = 27). Plasma levels of tumour necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6) and complement SC5b-9 were analysed by enzyme-linked immunosorbent assay (ELISA) 7 days after surgery. RESULTS: There were no significant between-group differences regarding the time course of TNF-alpha, IL-6 and complement SC5b-9 plasma level changes, the infection rate, or the length of hospital stay. CONCLUSION: In comparison to the impact of surgery on cytokine and complement levels, the transfusion of autologous buffy coat is not relevant..
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2001 |
---|---|
Erschienen: |
2001 |
Enthalten in: |
Zur Gesamtaufnahme - volume:81 |
---|---|
Enthalten in: |
Vox sanguinis - 81(2001), 3, Seite 180-186 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Tolksdorf, Bernd, 1960- [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
First published: 28 July 2009 Gesehen am 15.02.2021 |
---|
Umfang: |
7 |
---|
doi: |
10.1046/j.1423-0410.2001.00106.x |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
1748282158 |
---|
LEADER | 01000caa a2200265 4500 | ||
---|---|---|---|
001 | 1748282158 | ||
003 | DE-627 | ||
005 | 20230426072736.0 | ||
007 | cr uuu---uuuuu | ||
008 | 210215s2001 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1046/j.1423-0410.2001.00106.x |2 doi | |
035 | |a (DE-627)1748282158 | ||
035 | |a (DE-599)KXP1748282158 | ||
035 | |a (OCoLC)1341393240 | ||
040 | |a DE-627 |b ger |c DE-627 |e rda | ||
041 | |a eng | ||
100 | 1 | |a Tolksdorf, Bernd |d 1960- |e verfasserin |0 (DE-588)121840255 |0 (DE-627)705673197 |0 (DE-576)29291248X |4 aut | |
245 | 1 | 0 | |a Humoral immune response to autologous blood transfusion in hip surgery |b whole blood versus packed red cells and plasma |c B. Tolksdorf, T. Frietsch, M. Quintel, M. Kirschfink, P. Becker, A. Lorentz |
264 | 1 | |c 2001 | |
300 | |a 7 | ||
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a First published: 28 July 2009 | ||
500 | |a Gesehen am 15.02.2021 | ||
520 | |a BACKGROUND AND OBJECTIVES: The immune response to the transfused autologous buffy coat content in whole blood has, to date, not been studied in detail. SUBJECTS AND METHODS: Patients undergoing hip arthroplasty were studied according to whether they received autologous whole blood (WB) (n = 30), autologous fresh-frozen plasma and buffy coat-poor red cells (RC) (n = 40), or no transfusion (NT) (n = 27). Plasma levels of tumour necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6) and complement SC5b-9 were analysed by enzyme-linked immunosorbent assay (ELISA) 7 days after surgery. RESULTS: There were no significant between-group differences regarding the time course of TNF-alpha, IL-6 and complement SC5b-9 plasma level changes, the infection rate, or the length of hospital stay. CONCLUSION: In comparison to the impact of surgery on cytokine and complement levels, the transfusion of autologous buffy coat is not relevant. | ||
650 | 4 | |a Adult | |
650 | 4 | |a Aged | |
650 | 4 | |a Antibody Formation | |
650 | 4 | |a Arthroplasty, Replacement, Hip | |
650 | 4 | |a Blood Component Transfusion | |
650 | 4 | |a Blood Preservation | |
650 | 4 | |a Blood Transfusion, Autologous | |
650 | 4 | |a Cohort Studies | |
650 | 4 | |a Complement Membrane Attack Complex | |
650 | 4 | |a Complement System Proteins | |
650 | 4 | |a Cryopreservation | |
650 | 4 | |a Female | |
650 | 4 | |a Glycoproteins | |
650 | 4 | |a Humans | |
650 | 4 | |a Infections | |
650 | 4 | |a Inflammation Mediators | |
650 | 4 | |a Interleukin-6 | |
650 | 4 | |a Length of Stay | |
650 | 4 | |a Male | |
650 | 4 | |a Middle Aged | |
650 | 4 | |a Time Factors | |
650 | 4 | |a Tumor Necrosis Factor-alpha | |
700 | 1 | |a Frietsch, Thomas |d 1962- |e verfasserin |0 (DE-588)12171022X |0 (DE-627)081483112 |0 (DE-576)292842716 |4 aut | |
700 | 1 | |a Quintel, Michael |d 1954- |e verfasserin |0 (DE-588)1160944660 |0 (DE-627)1024324494 |0 (DE-576)506261522 |4 aut | |
700 | 1 | |a Kirschfink, Michael |e verfasserin |0 (DE-588)120927152 |0 (DE-627)080974457 |0 (DE-576)292452411 |4 aut | |
700 | 1 | |a Becker, P. |e verfasserin |4 aut | |
700 | 1 | |a Weiler-Lorentz, Arnulf |e verfasserin |0 (DE-588)123419466X |0 (DE-627)1759088617 |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Vox sanguinis |d Oxford [u.a.] : Wiley-Blackwell, 1956 |g 81(2001), 3, Seite 180-186 |h Online-Ressource |w (DE-627)300897936 |w (DE-600)1483587-3 |w (DE-576)09440402X |x 1423-0410 |7 nnns |
773 | 1 | 8 | |g volume:81 |g year:2001 |g number:3 |g pages:180-186 |g extent:7 |
856 | 4 | 0 | |u https://doi.org/10.1046/j.1423-0410.2001.00106.x |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
856 | 4 | 0 | |u https://onlinelibrary.wiley.com/doi/abs/10.1046/j.1423-0410.2001.00106.x |x Verlag |z lizenzpflichtig |3 Volltext |
912 | |a GBV_USEFLAG_U | ||
912 | |a GBV_ILN_2013 | ||
912 | |a ISIL_DE-16-250 | ||
912 | |a SYSFLAG_1 | ||
912 | |a GBV_KXP | ||
912 | |a SSG-OLC-PHA | ||
912 | |a GBV_ILN_11 | ||
912 | |a GBV_ILN_20 | ||
912 | |a GBV_ILN_22 | ||
912 | |a GBV_ILN_23 | ||
912 | |a GBV_ILN_24 | ||
912 | |a GBV_ILN_31 | ||
912 | |a GBV_ILN_32 | ||
912 | |a GBV_ILN_39 | ||
912 | |a GBV_ILN_40 | ||
912 | |a GBV_ILN_60 | ||
912 | |a GBV_ILN_62 | ||
912 | |a GBV_ILN_63 | ||
912 | |a GBV_ILN_69 | ||
912 | |a GBV_ILN_70 | ||
912 | |a GBV_ILN_73 | ||
912 | |a GBV_ILN_74 | ||
912 | |a GBV_ILN_90 | ||
912 | |a GBV_ILN_95 | ||
912 | |a GBV_ILN_100 | ||
912 | |a GBV_ILN_101 | ||
912 | |a GBV_ILN_105 | ||
912 | |a GBV_ILN_110 | ||
912 | |a GBV_ILN_120 | ||
912 | |a GBV_ILN_138 | ||
912 | |a GBV_ILN_150 | ||
912 | |a GBV_ILN_151 | ||
912 | |a GBV_ILN_161 | ||
912 | |a GBV_ILN_170 | ||
912 | |a GBV_ILN_171 | ||
912 | |a GBV_ILN_206 | ||
912 | |a GBV_ILN_224 | ||
912 | |a GBV_ILN_266 | ||
912 | |a GBV_ILN_285 | ||
912 | |a GBV_ILN_293 | ||
912 | |a GBV_ILN_370 | ||
912 | |a GBV_ILN_602 | ||
912 | |a GBV_ILN_636 | ||
912 | |a GBV_ILN_647 | ||
912 | |a GBV_ILN_702 | ||
912 | |a GBV_ILN_2001 | ||
912 | |a GBV_ILN_2003 | ||
912 | |a GBV_ILN_2004 | ||
912 | |a GBV_ILN_2005 | ||
912 | |a GBV_ILN_2006 | ||
912 | |a GBV_ILN_2007 | ||
912 | |a GBV_ILN_2008 | ||
912 | |a GBV_ILN_2009 | ||
912 | |a GBV_ILN_2010 | ||
912 | |a GBV_ILN_2011 | ||
912 | |a GBV_ILN_2014 | ||
912 | |a GBV_ILN_2015 | ||
912 | |a GBV_ILN_2018 | ||
912 | |a GBV_ILN_2020 | ||
912 | |a GBV_ILN_2021 | ||
912 | |a GBV_ILN_2025 | ||
912 | |a GBV_ILN_2026 | ||
912 | |a GBV_ILN_2027 | ||
912 | |a GBV_ILN_2031 | ||
912 | |a GBV_ILN_2034 | ||
912 | |a GBV_ILN_2037 | ||
912 | |a GBV_ILN_2038 | ||
912 | |a GBV_ILN_2039 | ||
912 | |a GBV_ILN_2044 | ||
912 | |a GBV_ILN_2048 | ||
912 | |a GBV_ILN_2049 | ||
912 | |a GBV_ILN_2050 | ||
912 | |a GBV_ILN_2055 | ||
912 | |a GBV_ILN_2056 | ||
912 | |a GBV_ILN_2057 | ||
912 | |a GBV_ILN_2061 | ||
912 | |a GBV_ILN_2064 | ||
912 | |a GBV_ILN_2068 | ||
912 | |a GBV_ILN_2088 | ||
912 | |a GBV_ILN_2093 | ||
912 | |a GBV_ILN_2106 | ||
912 | |a GBV_ILN_2108 | ||
912 | |a GBV_ILN_2110 | ||
912 | |a GBV_ILN_2111 | ||
912 | |a GBV_ILN_2112 | ||
912 | |a GBV_ILN_2113 | ||
912 | |a GBV_ILN_2118 | ||
912 | |a GBV_ILN_2119 | ||
912 | |a GBV_ILN_2122 | ||
912 | |a GBV_ILN_2129 | ||
912 | |a GBV_ILN_2143 | ||
912 | |a GBV_ILN_2144 | ||
912 | |a GBV_ILN_2147 | ||
912 | |a GBV_ILN_2148 | ||
912 | |a GBV_ILN_2152 | ||
912 | |a GBV_ILN_2153 | ||
912 | |a GBV_ILN_2188 | ||
912 | |a GBV_ILN_2190 | ||
912 | |a GBV_ILN_2232 | ||
912 | |a GBV_ILN_2336 | ||
912 | |a GBV_ILN_2470 | ||
912 | |a GBV_ILN_2472 | ||
912 | |a GBV_ILN_2507 | ||
912 | |a GBV_ILN_2522 | ||
912 | |a GBV_ILN_2548 | ||
912 | |a GBV_ILN_4012 | ||
912 | |a GBV_ILN_4035 | ||
912 | |a GBV_ILN_4037 | ||
912 | |a GBV_ILN_4046 | ||
912 | |a GBV_ILN_4112 | ||
912 | |a GBV_ILN_4125 | ||
912 | |a GBV_ILN_4126 | ||
912 | |a GBV_ILN_4242 | ||
912 | |a GBV_ILN_4246 | ||
912 | |a GBV_ILN_4249 | ||
912 | |a GBV_ILN_4251 | ||
912 | |a GBV_ILN_4305 | ||
912 | |a GBV_ILN_4306 | ||
912 | |a GBV_ILN_4307 | ||
912 | |a GBV_ILN_4313 | ||
912 | |a GBV_ILN_4322 | ||
912 | |a GBV_ILN_4323 | ||
912 | |a GBV_ILN_4324 | ||
912 | |a GBV_ILN_4325 | ||
912 | |a GBV_ILN_4326 | ||
912 | |a GBV_ILN_4333 | ||
912 | |a GBV_ILN_4334 | ||
912 | |a GBV_ILN_4335 | ||
912 | |a GBV_ILN_4336 | ||
912 | |a GBV_ILN_4338 | ||
912 | |a GBV_ILN_4393 | ||
912 | |a GBV_ILN_4700 | ||
936 | u | w | |d 81 |j 2001 |e 3 |h 180-186 |g 7 |
951 | |a AR | ||
952 | |d 81 |j 2001 |e 3 |h 180-186 |g 7 | ||
980 | |2 2013 |1 01 |x DE-16-250 |b 3853614507 |c 00 |f --%%-- |d --%%-- |e --%%-- |j --%%-- |y l01 |z 15-02-21 | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 00 |s s |a hd2001 | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 01 |s s |0 (DE-627)1410508463 |a wissenschaftlicher Artikel (Zeitschrift) | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 02 |s s |a per_6 | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 03 |s s |a s_7 | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 04 |s p |0 (DE-627)1497889677 |a Frietsch, Thomas | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 04 |s k |0 (DE-627)1416467890 |a Klinik für Anästhesiologie und Operative Intensivmedizin | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 04 |s s |0 (DE-627)1410501914 |a Verfasser | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 04 |s s |a pos_2 | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 05 |s p |0 (DE-627)1759088889 |a Quintel, Michael | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 05 |s k |0 (DE-627)1416467890 |a Klinik für Anästhesiologie und Operative Intensivmedizin | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 05 |s s |0 (DE-627)1410501914 |a Verfasser | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 05 |s s |a pos_3 | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 06 |s p |0 (DE-627)1450201806 |a Kirschfink, Michael | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 06 |s k |0 (DE-627)1416741488 |a Institut für Immunologie und Serologie | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 06 |s s |0 (DE-627)1410501914 |a Verfasser | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 06 |s s |a pos_4 | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 07 |s p |0 (DE-627)1759088722 |a Weiler-Lorentz, Arnulf | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 07 |s k |0 (DE-627)1416467890 |a Klinik für Anästhesiologie und Operative Intensivmedizin | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 07 |s s |0 (DE-627)1410501914 |a Verfasser | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 07 |s s |a pos_6 |